-+ 0.00%
-+ 0.00%
-+ 0.00%

Avalyn to present 4-year ATLAS data for inhaled pirfenidone AP01 at EULAR 2026

PUBT·05/21/2026 12:01:55
Listen to the news
Avalyn to present 4-year ATLAS data for inhaled pirfenidone AP01 at EULAR 2026
  • Avalyn Pharma flagged additional long-term data from the ATLAS open-label extension study of AP01, an inhaled version of pirfenidone, with results scheduled for presentation at EULAR 2026 on June 6 in London.
  • The update is set to focus on long-term tolerability in patients with progressive pulmonary fibrosis treated for up to four years.
  • Avalyn also pointed to prior studies suggesting AP01 could help preserve lung function while improving tolerability versus historical oral pirfenidone, a positioning that supports its ongoing Phase 2b MIST trial in progressive pulmonary fibrosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalyn Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210800PRIMZONEFULLFEED9724350) on May 21, 2026, and is solely responsible for the information contained therein.